Prior to his retirement from Bristol-Myers Squibb (BMS), Dr Smyth led oncology medical affairs in the US, including the US life-cycle development of paclitaxel (Taxol), carboplatin (Paraplatin) and ifosfamide (Ifex).
Prior to joining BMS, Dr Smyth served as vice president of medical affairs with American Oncology Resources, now US Oncology.
Athanase Lavidas, lead director of the Ariad board, said: “Dr Smyth’s appointment to the board is part of an ongoing process to add exceptional individuals to the Ariad board, a process that dates back to 2008. Dr Smyth will serve as an independent director in Class Two.”